Skip to main content

Table 2 Treatment-emergent adverse events (safety population; N [%]; incidence ≥ 5%)

From: Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study

Adverse event Most recent or current episode of bipolar I disorder
All patients (n = 199) Depressed episode (n = 117) Non-Depressed episode (n = 82)
At least one adverse event 169 (84.9%) 96 (82.1) 73 (89.0%)
Akathisia 61 (30.7%) 40 (34.2%) 21 (25.6%)
Nasopharyngitis 53 (26.6%) 24 (20.5%) 29 (35.4%)
Nausea 24 (12.1%) 12 (10.3%) 12 (14.6%)
Somnolence 24 (12.1%) 10 (8.5%) 14 (17.1%)
Weight increased 17 (8.5%) 8 (6.8%) 9 (11.0%)
Headache 16 (8.0%) 7 (6.0%) 9 (11.0%)
Parkinsonism 15 (7.5%) 10 (8.5%) 5 (6.1%)
Disease progression 13 (6.5%) 9 (7.7%) 4 (4.9%)
Vomiting 13 (6.5%) 8 (6.8%) 5 (6.1%)
Diarrhoea 10 (5.0%) 4 (3.4%) 6 (7.3%)
Dystonia 10 (5.0%) 5 (4.3%) 5 (6.1%)